Nefiracetam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nefiracetam
Accession Number
DB13082
Type
Small Molecule
Groups
Investigational
Description

Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
1JK12GX30N
CAS number
77191-36-7
Weight
Average: 246.31
Monoisotopic: 246.136827828
Chemical Formula
C14H18N2O2
InChI Key
NGHTXZCKLWZPGK-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)
IUPAC Name
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)ethanimidic acid
SMILES
CC1=CC=CC(C)=C1N=C(O)CN1CCCC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Nefiracetam.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nefiracetam.Approved, Investigational
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Nefiracetam.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Cyclosporine.Approved, Investigational, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Desvenlafaxine.Approved, Investigational
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nefiracetam.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Fluoxetine.Approved, Vet Approved
IsocarboxazidThe therapeutic efficacy of Nefiracetam can be increased when used in combination with Isocarboxazid.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Nefiracetam.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Magnesium hydroxide.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Neomycin.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Polymyxin B Sulfate.Approved, Vet Approved
RopiniroleNefiracetam may increase the sedative activities of Ropinirole.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Nefiracetam.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Venlafaxine.Approved
ZolpidemNefiracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
71157
PubChem Substance
347829207
ChemSpider
64299
ChEBI
135004
ChEMBL
CHEMBL260829
Wikipedia
Nefiracetam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlzheimer's Disease (AD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.349 mg/mLALOGPS
logP1.31ALOGPS
logP2.31ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)4.72ChemAxon
pKa (Strongest Basic)1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.35 m3·mol-1ChemAxon
Polarizability26.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004j-7920010011-f3cb0b77efee19ef8d89

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Anilides / m-Xylenes / N-arylamides / Pyrrolidine-2-ones / N-alkylpyrrolidines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Alpha-amino acid or derivatives / Anilide / N-arylamide / Xylene / M-xylene / 2-pyrrolidone / Monocyclic benzene moiety / Benzenoid / N-alkylpyrrolidine / Pyrrolidone
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 20:49 / Updated on August 02, 2018 06:47